- Home
- Publications
- Publication Search
- Publication Details
Title
Safety evaluation of ruxolitinib for treating myelofibrosis
Authors
Keywords
-
Journal
Expert Opinion On Drug Safety
Volume 13, Issue 7, Pages 967-976
Publisher
Informa Healthcare
Online
2014-06-04
DOI
10.1517/14740338.2014.916273
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Therapeutic Targeting of the JAK/STAT Pathway
- (2013) Saara Aittomäki et al. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
- Scouting out the neighborhood in AIDS-related lymphoma
- (2013) K. Dunleavy et al. BLOOD
- Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report
- (2013) A. Tefferi et al. BLOOD
- Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
- (2013) F. Cervantes et al. BLOOD
- The JAK-inhibitor ruxolitinib impairs dendritic cell function in vitro and in vivo
- (2013) A. Heine et al. BLOOD
- Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis?
- (2013) A. Heine et al. BLOOD
- Romiplostim-induced myelofibrosis
- (2013) A. Rashidi et al. BLOOD
- Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinibversusbest available therapy
- (2013) Claire N. Harrison et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase I study of panobinostat (LBH589) in patients with primary myelofibrosis (PMF) and post-polycythaemia vera/essential thrombocythaemia myelofibrosis (post-PV/ET MF)
- (2013) John Mascarenhas et al. BRITISH JOURNAL OF HAEMATOLOGY
- A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea
- (2013) Srdan Verstovsek et al. CANCER
- An Opportunistic Infection Associated With Ruxolitinib, a Novel Janus Kinase 1,2 Inhibitor
- (2013) Nicholas G. Wysham et al. CHEST
- Jakpot! New small molecules in autoimmune and inflammatory diseases
- (2013) Kamran Ghoreschi et al. EXPERIMENTAL DERMATOLOGY
- Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib
- (2013) B. S. Wilkins et al. HAEMATOLOGICA
- Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies
- (2013) R. A. Mesa et al. HAEMATOLOGICA
- Population Pharmacokinetic Analysis of Orally-Administered Ruxolitinib (INCB018424 Phosphate) in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia Myelofibrosis (PET MF)
- (2013) Xuejun Chen et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
- (2013) Moshe Talpaz et al. Journal of Hematology & Oncology
- Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis
- (2013) G Caocci et al. LEUKEMIA
- Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib
- (2013) M Massa et al. LEUKEMIA
- Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study
- (2013) J V Jovanovic et al. LEUKEMIA
- Progressive Multifocal Leukoencephalopathy Associated with Ruxolitinib
- (2013) Rowan Wathes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
- (2013) J. Nangalia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms
- (2013) Thorsten Klampfl et al. NEW ENGLAND JOURNAL OF MEDICINE
- Bilateral Toxoplasmosis Retinitis Associated with Ruxolitinib
- (2013) Roger A. Goldberg et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ruxolitinib for the Treatment of Myelofibrosis: A NICE Single Technology Appraisal
- (2013) Ros Wade et al. PHARMACOECONOMICS
- Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes
- (2013) Srdan Verstovsek et al. OncoTargets and Therapy
- Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia
- (2012) A. Eghtedar et al. BLOOD
- Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia
- (2012) S. L. Maude et al. BLOOD
- Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012
- (2012) Donal P. McLornan et al. BRITISH JOURNAL OF HAEMATOLOGY
- Heterodimeric JAK–STAT activation as a mechanism of persistence to JAK2 inhibitor therapy
- (2012) Priya Koppikar et al. NATURE
- A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
- (2012) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
- (2012) Claire Harrison et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis
- (2011) P. Guglielmelli et al. BLOOD
- The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers
- (2011) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- The Effect of CYP3A4 Inhibition or Induction on the Pharmacokinetics and Pharmacodynamics of Orally Administered Ruxolitinib (INCB018424 Phosphate) in Healthy Volunteers
- (2011) Jack G. Shi et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Kinase domain mutations confer resistance to novel inhibitors targeting JAK2V617F in myeloproliferative neoplasms
- (2011) A Deshpande et al. LEUKEMIA
- Serious Adverse Events During Ruxolitinib Treatment Discontinuation in Patients With Myelofibrosis
- (2011) Ayalew Tefferi et al. MAYO CLINIC PROCEEDINGS
- Genetic and Epigenetic Complexity in Myeloproliferative Neoplasms
- (2011) N. C. P. Cross Hematology-American Society of Hematology Education Program
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
- Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans
- (2010) A. D. Shilling et al. DRUG METABOLISM AND DISPOSITION
- Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
- (2010) Srdan Verstovsek et al. NEW ENGLAND JOURNAL OF MEDICINE
- A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process
- (2009) Giovanni Barosi et al. BRITISH JOURNAL OF HAEMATOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started